
From: Jeffrey Epstein <jeevacation@gmail.com>
Sent: Monday, February 24, 2014 9:23 PM
To: Lesley Groff; Richard Kahn
Subject: Re: Joe Thakuria

give him 10k

=div class="gmail_quote">On Mon, Feb 24, 2014 at 5:21 PM, Lesley Groff <[REDACTED]>
<mailto:[REDACTED]> > wrote:

Sent from my =Phone

Begin forwarded message:

From: Joseph Thakuria <[REDACTED]> <mailto:[REDACTED]>
Date:=February 24, 2014, 4:08:44 PM EST
To: Lesley Groff <[REDACTED]>;
Cc: Rich Kahn <[REDACTED]>
Subject: Re: Jeffr=y Epstein

Really?

Ok, done (pending approval through Partners/MGH =RB for my formal research study - about 5 weeks as we discussed).

Can we get a little additional software budget for s=condary analyses? At least the \$4K worth we would have gotten with an exom=? The rationale for this is so we don't have to completely rely only &=uot;black box" interpretation by Illumina. In my experience, Illumina's genome interpretation has been historically subpar. Not surprising si=ce they are primarily a next gen DNA sequencing instrumentation company - =ot really focused on analyses and genomic analyses software (though they d= have their own). It may be that we don't pull up a lot of extra info =ith additional software. But we won't know that one way or the other r=lying only on Illumina's interpretation.

Anyway, let me know. The budget/invoice is complete if =e all we are going after is one item: a rapid turnaround whole genome thro=gh Illumina for \$11,400. I do think this is the best (highest quality) whole genome you can get for the money but it is disappointing to me that thei= pricing has been essentially unchanged for years (the reason I expected t=is to be in the \$5K range). I do think I can find a whole genome for aroun= \$5K (perhaps through CGI) but again I'd question the quality of that =enome. (That was the research rationale for getting 1 from Illumina and 1 =from CGI to compare results if the funding were available for this).

Let me know if this needs any further clarification.

Thanks again,
Joe

On Mon, Feb 24, 2014 at 3:=6 PM, Lesley Groff <mailto:[REDACTED]> > wrote:

Hi Joe&h=llip;below is Jeffrey's reply:

let= start and do the full genome with rapid turn around. 11,400

On Feb 24, 2014, at 3:38=PM, Joseph Thakuria <mailto:[REDACTED]> > wrote:

Hi Lesley and Rich,

Lesley, can you forward the following info to Jeffrey?

So when I sent the initial invoice I didn't have =he actual whole genome costs through Illumina which are \$9500 for a normal=turn around time and \$11,400 for "rapid turn around time". The r=pid turn around time isn't necessary in Jeffrey's case. And, in my=opinion, if the budget is only \$5000, I think the most bang for his buck (=nd this is what I would do for myself with only \$5000 to spend) is to get =n exome done. I should be able to get this through Ambry and through the s=me research protocol we'll be suing for the YPO study participants for=\$1000. I would then use the remainder to purchase genome analyses tools (t=ere won't be enough for any servers) to perform secondary analyses on =he exome.

The exome only represents around 1.5% of the genome - b=t this is the medically most important part of the genome (at least given =ur current knowledge) and represents all the coding regions in all our 20,00+ genes.

If this sounds good to Jeffrey, I'll produce a fina= budget before the end of the week that specifies which of the tools we l=;ll be able to get with the remaining \$4000. (I need to finish pricing and=tallying up features among the 6 I listed to determine which one(s) will g=t.

This won't of course cover any cellular work or oth=r items in the full invoice but I would still recommend moving at least so=e fibroblast cell lines aliquots from the PGP to our new study so we can w=rk on those when funding from other sources is available.

I would also just throw out there for Jeffrey's con=ideration that the same ambitious protocol for a stripped down clinical ne=t generation DNA sequencing laboratory could be pursued with a similar bud=et on the commercial side - and I've already been in discussion with o=thers about funding this effort. Having followed this space since 2005 I ca= say the timing is very good for this type of business right now. Again, i= hasn't even been more than a year that this technology has transition=d into clinical care. So if this is something Jeffrey would be interested =n pursuing as an investor with an equity stake, rather than as a philanthr=pic grant for academic research, that would be another route for going ahe=d with the full project that he may be interested in discussing further.</=iv>

Rich, I'll leave it to you on how you'd like to handle the \$5000 invoice. I could receive this as a lump sum and account for how it is spent. I would expect all of it to be used up before the end of the summer. We can also arrange it so that as the various vendors (sequencing and software) provide invoices, your office pays them directly. Either way is fine with me. I don't have a preference.

Thanks and let me know if I can provide any clarifications. Again, I'll follow up with an invoice capped at \$5K before the end-of the week (assuming you agree with the above).

Joe Thakuria

<div class="gmail_quote">On Fri, Feb 21, 2014 at 6:34 PM, Lesley Groff

<mailto:[REDACTED]> wrote:

Hello Joe. I have Jeffrey's accountant on this email as well, Rich Kahn . Jeffrey has told Rich he would like to do a \$5000 genetic work up done for the time being. Could you coordinate with Rich regarding payment/next steps?

Thank you,
Lesley
Assistant to Jeffrey Epstein

Sent from my iPhone

The information contained in this communication is confidential, may be attorney-client privileged, may constitute inside information, and is intended only for the use of the addressee. It is the property of Jeffrey Epstein. Unauthorized use, disclosure or copying of this communication or any part thereof is strictly prohibited and may be unlawful. If you have received this communication in error, please notify us immediately by return e-mail or by e-mail to jeevacation@gmail.com, and destroy this communication and all copies thereof, including all attachments. copyright -all rights reserved